Laughlin Brady S, Bhangoo Ronik S, Thorpe Cameron S, Golafshar Michael A, DeWees Todd A, Anderson Justin D, Vern-Gross Tamara Z, McGee Lisa A, Wong William W, Halyard Michele Y, Keole Sameer R, Vargas Carlos E
Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, United States.
Front Oncol. 2022 Aug 26;12:920739. doi: 10.3389/fonc.2022.920739. eCollection 2022.
We present Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for patients undergoing adjuvant radiotherapy for breast cancer with curative intent. We describe the frequency and severity of PRO-CTCAE and analyze them with respect to dose fractionation.
Patients were included in this study if they were treated with curative intent for breast cancer and enrolled on a prospective registry. Patients must have completed at least one baseline and one post-radiation survey that addressed PRO-CTCAE. For univariate and multivariate analysis, categorical variables were analyzed by Fisher's exact test and continuous variables by Wilcoxon rank sum test. PRO-CTCAE items graded ≥2 and ≥3 were analyzed between patients who received hypofractionation (HF) versus standard conventional fractionation (CF) therapy by the Chi-square test.
Three hundred thirty-one patients met inclusion criteria. Pathologic tumor stage was T1-T2 in 309 (94%) patients. Eighty-seven (29%) patients were node positive. Two hundred forty-seven patients (75%) experienced any PRO-CTCAE grade ≥2, and 92 (28%) patients experienced any PRO-CTCAE grade ≥3. CF was found to be associated with an increased risk of grade ≥3 skin toxicity, swallowing, and nausea (all p < 0.01). HF (OR 0.48, p < 0.01) was significant in the multivariate model for decreased risk of any occurrence of PRO-CTCAE ≥3.
Our study reports one of the first clinical experiences utilizing multiple PRO-CTCAE items for patients with breast cancer undergoing radiation therapy with curative intent. Compared with CF, HF was associated with a significant decrease in any PRO-CTCAE ≥3 after multivariate analysis.
我们提出了用于接受根治性乳腺癌辅助放疗患者的患者报告的不良事件通用术语标准版本(PRO-CTCAE)。我们描述了PRO-CTCAE的频率和严重程度,并就剂量分割进行了分析。
如果患者接受了根治性乳腺癌治疗并纳入前瞻性登记,则纳入本研究。患者必须完成至少一项涉及PRO-CTCAE的基线和一项放疗后调查。对于单变量和多变量分析,分类变量采用Fisher精确检验分析,连续变量采用Wilcoxon秩和检验分析。通过卡方检验分析接受大分割(HF)与标准常规分割(CF)治疗的患者之间分级≥2和≥3的PRO-CTCAE项目。
331例患者符合纳入标准。309例(94%)患者的病理肿瘤分期为T1-T2。87例(29%)患者淋巴结阳性。247例(75%)患者经历了任何PRO-CTCAE分级≥2,92例(28%)患者经历了任何PRO-CTCAE分级≥3。发现CF与≥3级皮肤毒性、吞咽和恶心风险增加相关(所有p<0.01)。在多变量模型中,HF(OR 0.48,p<0.01)对于降低任何PRO-CTCAE≥3发生的风险具有显著意义。
我们的研究报告了首批将多个PRO-CTCAE项目用于接受根治性放疗的乳腺癌患者的临床经验之一。与CF相比,多变量分析后HF与任何PRO-CTCAE≥3的显著降低相关。